Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
Ontology highlight
ABSTRACT: Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration. However, as most prostate cancer patients acquire castration resistance, additional therapeutic solutions are necessary. Although anti-androgens, such as enzalutamide, have been used to treat castration-resistant prostate cancer (CRPC), enzalutamide-resistant CRPC (Enz-resistant CRPC) has emerged. Therefore, development of novel treatments for Enz-resistant CRPC is urgent. In this study, we found a novel anti-androgen called pinostilbene through screening with a GAL4-transactivation assay. We confirmed that pinostilbene directly binds to androgen receptor (AR) and inhibits its activation and transl
SUBMITTER: Shin WS
PROVIDER: S-EPMC10550987 | biostudies-literature | 2023 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA